Skip to main content

Novartis Ag ADR(NVS-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Novartis Canada's statement on CADTH draft recommendations for LEQVIO® (inclisiran)

Newswire.ca - Thu Mar 21, 12:41PM CDT

MONTRÉAL, March 21, 2024 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) for LEQVIO® (inclisiran).

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe